BiotechTube

ISA101b + Cemiplimab

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Squamous Cell Carcinoma of the Oropharynx

Conditions

Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive

Trial Timeline

Nov 30, 2018 → Jun 1, 2025

NCT ID
NCT03669718

About ISA101b + Cemiplimab

ISA101b + Cemiplimab is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Squamous Cell Carcinoma of the Oropharynx. The current trial status is unknown. This product is registered under clinical trial identifier NCT03669718. Target conditions include Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive.

What happened to similar drugs?

4 of 20 similar drugs in Squamous Cell Carcinoma of the Oropharynx were approved

Approved (4) Terminated (2) Active (14)
✅Pembrolizumab + Carboplatin + PaclitaxelMerckApproved
✅erlotinib [Tarceva]RocheApproved
✅erlotinib [Tarceva]RocheApproved
✅Platinum-based chemotherapy + Bevacizumab [Avastin]RocheApproved
🔄CT-P51 + EU-approved KeytrudaCelltrionPhase 3
🔄Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
🔄Patritumab Deruxtecan + Platinum-based chemotherapyDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
12
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03669718Phase 2UNKNOWN

Competing Products

20 competing products in Squamous Cell Carcinoma of the Oropharynx

See all competitors
ProductCompanyStageHype Score
AFM24 + SNK01AffimedPhase 1/2
14
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
35
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
Cemiplimab + CetuximabEli LillyPhase 2
42
Necitumumab-Gemcitabine-CisplatinEli LillyPhase 2
27
BB-401Benitec BiopharmaPhase 2
25
Ramucirumab + PaclitaxelEli LillyPhase 2
35
Gemcitabine + ACR-368Acrivon TherapeuticsPhase 2
32
CT-P51 + EU-approved KeytrudaCelltrionPhase 3
47
Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue MedicationDaiichi SankyoPhase 1/2
39
Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
47
I-DXd + Rescue MedicationDaiichi SankyoPhase 1/2
39
Patritumab + Cetuximab + Cisplatin + CarboplatinDaiichi SankyoPhase 1
29
Patritumab Deruxtecan + Platinum-based chemotherapyDaiichi SankyoPhase 3
44
Tivantinib + Placebo + ErlotinibDaiichi SankyoPhase 3
32
Avelumab + enfortumab vedotinAstellas PharmaPhase 2
42
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
avelumab + Bempegaldesleukin + talazoparib + enzalutamideAstellas PharmaPhase 1/2
24
Drug Combination TherapySun PharmaceuticalPhase 2
42